Grifols' proposed acquisition of Talecris
Provided analysis on behalf of Grifols in connection with its acquisition of Talecris, both companies involved in the manufacture and sale of plasma-derived therapies used to treat a range of medical conditions. Evaluated possible coordinated effects concerns and assessed the merger specificity of claimed efficiencies in analysis presented to the FTC. Subsequent to a second request, FTC approved the transaction after Grifols agreed to a consent decree with provisions to facilitate entry.